1 / 11

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60. Design and eligibility criteria of primary prevention trials. Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60.

cian
Download Presentation

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

  2. Design and eligibility criteria of primary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

  3. Serious vascular events in primary prevention trials-proportional effects of aspirin allocation Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

  4. Serious vascular events in primary prevention Trials-subgroup analyses ATT Collaboration. Lancet 2009;373:1849-60

  5. Comparison of proportional and absolute effects of aspirin in primary and secondary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

  6. Selected outcomes in primary and secondary prevention trials of aspirin, by sex ATT Collaboration. Lancet 2009;373:1849-60

  7. Stroke subtypes in primary and secondary prevention trials ATT Collaboration. Lancet 2009;373:1849-60

  8. Mortality by cause in primary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

  9. Rate ratios (95% CI) associated with risk factors for selected outcomes in people with no known vascular disease in primary prevention trials Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:1849-60

  10. Predicted 5-year absolute eff ects of allocation to aspirin in different categories of age and sex in the primary and secondary prevention trials (ignoring non-vascular mortality) ATT Collaboration. Lancet 2009;373:1849-60

  11. Predicted 5-year absolute effects of allocation to aspirin in the primary prevention trials in different categories of 5-year risk (if untreated) of coronary heart disease (CHD) (ignoring non-vascular mortality) ATT Collaboration. Lancet 2009;373:1849-60

More Related